



C-RAD's cutting-edge SGRT solution selected for two proton therapy projects

C-RAD announced today a purchase order from the Belgium company Ion Beam Applications SA (IBA) to supply multiple Catalyst™ and Sentinel™ 4DCT systems as well as a multiyear service agreement.

C-RAD and IBA have several successful collaborations at multiple sites globally. This latest project includes an installation at two prominent Chinese proton therapy centers.

Proton therapy and the high demands for uncompromised accuracy and operational efficiency within the field lies at the centre of technological advancement at C-RAD. One of many reasons why C-RAD is the SGRT market leader within the proton field.

The C-RAD Catalyst PT is a surface guided radiation therapy system (SGRT) version based on the patented Catalyst technology and software for use in proton and particle therapy, it is a complete solution for high precision patient positioning, intra-fraction motion management, and respiratory gating.

"I am excited to work with the customers and IBA on the implementation of our advanced surface tracking solutions here in China." says Kurt Xiaodong Wang, President at C-RAD in China "China has a big unmet demand for cancer care. Our customers show a huge interest in adapting surface tracking both in photon and proton therapy. This interest made C-RAD the distant market leader for surface tracking in China."

"We are delighted to announce this important milestone in the implementation of our strategy to make surface tracking standard of care in advanced radiation therapy." says Tim Thurn, CEO and President at C-RAD AB. "Proton therapy is the spearhead of precision radiation therapy. It has the potential to deliver the treatment dose with highest precision. Accurate patient positioning is crucial for a successful and safe treatment. We are looking forward to team up with the customer to contribute with our solutions to improve cancer care for patients in need."

The order has a total value of approximately 20 MSEK. Delivery and installation are expected to be commence during 2023.

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com



About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit <http://www.c-rad.com>

This information is information that C-Rad is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-12-20 14:10 CET.

Attachments

[C-RAD's cutting-edge SGRT solution selected for two proton therapy projects](#)